Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490678 | ||
| 003 | CHVBK | ||
| 005 | 20210128100506.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-015-0839-y |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-015-0839-y | ||
| 245 | 0 | 0 | |a Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery |h [Elektronische Daten] |c [Shinji Urakami, Takeshi Yuasa, Shinya Yamamoto, Mizuaki Sakura, Hajime Tanaka, Tatsuro Hayashi, Sho Uehara, Yasushi Inoue, Yasuhisa Fujii, Hitoshi Masuda, Iwao Fukui, Junji Yonese] |
| 520 | 3 | |a Background: To determine the indications for post-chemotherapy consolidative surgery in patients with clinical lymph node (LN) metastatic (cN+) urothelial carcinoma (UC). Methods: Sixty UC patients with measurable cN+ but without detectable systemic visceral/bone dissemination received induction platinum-based chemotherapy. Consolidative surgery was offered to all patients except for those with progressive disease. We retrospectively analyzed the clinicopathological response to induction chemotherapy and identified prognostic factors for overall survival (OS). Results: The primary cancer site was the urinary bladder in 31 patients (52%) and upper urinary tract in 29 (48%). The median number of chemotherapy courses was 4. Forty-five patients (75%) showed a clinically objective response to the induction chemotherapy. Fifty-one patients (85%) underwent subsequent consolidative surgery. Histopathological analysis indicated pT0 status in 10 (20%) and pN0 in 17 (33%). When all 60 patients were considered, clinical tumor response was found to be significantly correlated with achievement of pathological complete response. At the median follow-up of 22months, the median progression-free survival and OS periods were excellent: 18.6 and 31.6months, respectively. In the multivariate analysis, clinical tumor response was found to be an independent pre-surgical prognostic factor for OS, and pathologically negative lymph node, negative resection margin, more LNs removed, and negative lymphovascular invasion were found to be independent post-surgical prognostic parameters for OS. Conclusions: The median OS in induction chemotherapy followed by consolidative surgery was very encouraging. Our results suggest that achieving a good clinical response to pre-surgical induction chemotherapy is a good indication for subsequent consolidative surgery in UC patients with cN+ to improve OS through a good pathological response. | |
| 540 | |a Japan Society of Clinical Oncology, 2015 | ||
| 690 | 7 | |a Consolidative surgery |2 nationallicence | |
| 690 | 7 | |a Induction chemotherapy |2 nationallicence | |
| 690 | 7 | |a Lymph node metastasis |2 nationallicence | |
| 690 | 7 | |a Multimodality treatment |2 nationallicence | |
| 690 | 7 | |a Urothelial carcinoma |2 nationallicence | |
| 700 | 1 | |a Urakami |D Shinji |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Yuasa |D Takeshi |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Yamamoto |D Shinya |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Sakura |D Mizuaki |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Tanaka |D Hajime |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Hayashi |D Tatsuro |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Uehara |D Sho |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Inoue |D Yasushi |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Fujii |D Yasuhisa |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Masuda |D Hitoshi |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Fukui |D Iwao |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Yonese |D Junji |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1171-1178 |x 1341-9625 |q 20:6<1171 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-015-0839-y |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-015-0839-y |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Urakami |D Shinji |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yuasa |D Takeshi |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yamamoto |D Shinya |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sakura |D Mizuaki |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tanaka |D Hajime |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hayashi |D Tatsuro |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Uehara |D Sho |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Inoue |D Yasushi |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Fujii |D Yasuhisa |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Masuda |D Hitoshi |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Fukui |D Iwao |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yonese |D Junji |u Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, 105-8470, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1171-1178 |x 1341-9625 |q 20:6<1171 |1 2015 |2 20 |o 10147 | ||